FR08C0046I1 - Reconstitution in vitro de virus a arn de polarite negative segmentes - Google Patents

Reconstitution in vitro de virus a arn de polarite negative segmentes

Info

Publication number
FR08C0046I1
FR08C0046I1 FR08C0046C FR08C0046I1 FR 08C0046 I1 FR08C0046 I1 FR 08C0046I1 FR 08C0046 C FR08C0046 C FR 08C0046C FR 08C0046 I1 FR08C0046 I1 FR 08C0046I1
Authority
FR
France
Prior art keywords
segmented
polarity
rna viruses
negative rna
vitro reconstruction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0046(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916794.2A external-priority patent/GB9916794D0/en
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of FR08C0046I1 publication Critical patent/FR08C0046I1/fr
Application granted granted Critical
Publication of FR08C0046I2 publication Critical patent/FR08C0046I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR08C0046C 1999-07-14 2008-11-13 Reconstitution in vitro de virus a arn de polarite negative segmentes Active FR08C0046I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14364599P 1999-07-14 1999-07-14
GBGB9916794.2A GB9916794D0 (en) 1999-07-16 1999-07-16 In vitro virus reconstitution
PCT/GB2000/002710 WO2001004333A1 (fr) 1999-07-14 2000-07-14 Reconstitution in vitro de virus a arn de polarite negative segmentes

Publications (2)

Publication Number Publication Date
FR08C0046I1 true FR08C0046I1 (fr) 2009-01-02
FR08C0046I2 FR08C0046I2 (fr) 2011-11-25

Family

ID=26315773

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0046C Active FR08C0046I2 (fr) 1999-07-14 2008-11-13 Reconstitution in vitro de virus a arn de polarite negative segmentes

Country Status (12)

Country Link
EP (1) EP1194580B2 (fr)
AT (1) ATE353370T1 (fr)
AU (1) AU5998400A (fr)
CA (1) CA2379012C (fr)
CY (2) CY1106404T1 (fr)
DE (5) DE122007000061I2 (fr)
DK (1) DK1194580T4 (fr)
ES (1) ES2278621T5 (fr)
FR (1) FR08C0046I2 (fr)
LU (1) LU91367I2 (fr)
NL (4) NL300294I2 (fr)
WO (1) WO2001004333A1 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1086207T3 (da) 1998-06-12 2007-05-29 Sinai School Medicine Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
WO2002083896A2 (fr) * 2001-04-17 2002-10-24 Institut Pasteur Virus recombinant segmente a polarite negative contenant un segment d'arnv bicistronique avec duplication de sa sequence laterale 3' non codante, et vaccins et compositions therapeutiques le contenant
HUE050222T2 (hu) 2002-02-13 2020-11-30 Wisconsin Alumni Res Found Szignál influenzavírus-vektorok pakolására
FR2866031B1 (fr) * 2004-02-11 2012-10-19 David Francois Joseph Millet Chimere de virus pathogene emergent, medicament la contenant et utilisation en therapie antivirale
CA2559371C (fr) 2004-03-09 2014-07-08 Chiron Corporation Vaccins antigrippaux
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
AU2005318087B2 (en) 2004-12-24 2011-04-21 Abbott Biologicals B.V. Rescue of influenza virus
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
KR20080025171A (ko) 2005-06-21 2008-03-19 메드이뮨 백신즈 인코포레이티드 이종성 프로테아제를 발현시키기 위한 방법 및 조성물
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CN102727885A (zh) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 包含颗粒佐剂和免疫增强剂组合的流感疫苗
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
US20090304742A1 (en) 2005-11-04 2009-12-10 Novartis Vaccines And Diagnostics Srl Influenza vaccines with reduced amount of emulsion adjuvant
DK2368572T3 (da) 2005-11-04 2020-05-25 Seqirus Uk Ltd Adjuvansvacciner med ikke-virionantigener fremstillet fra influenza-virusser dyrket i cellekultur
WO2007052061A2 (fr) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions a tensioactif a phase aqueuse libre pour adjuver des vaccins antigrippaux sous-unitaires
US9387242B2 (en) 2005-12-02 2016-07-12 Icahn School Of Medicine At Mount Sinai Chimeric viruses presenting non-native surface proteins and uses thereof
WO2007085969A2 (fr) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg Vaccins contre la grippe contenant des hémaglutinines et des protéines matricielles
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
JP5491173B2 (ja) * 2006-04-19 2014-05-14 メディミューン，エルエルシー イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
CA3016948A1 (fr) 2006-09-11 2008-03-20 Seqirus UK Limited Fabrication de vaccins contre le virus grippal sans utiliser d'oeufs
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
WO2008147496A2 (fr) 2007-05-04 2008-12-04 Warf - Wisconsin Alumni Research Foundation Vaccins de la grippe vivants déficients en neuraminidase
WO2008156681A2 (fr) * 2007-06-14 2008-12-24 Yoshihiro Kawaoka Vecteurs d'adénovirus pour la production de virus de la grippe
CA2692200A1 (fr) 2007-06-27 2008-12-31 Novartis Ag Vaccins antigrippaux a faible teneur en additifs
EP2045323A1 (fr) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Constructions linéaires d'expression pour la production de particules de virus influenza
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP2889042A3 (fr) 2008-03-18 2015-10-14 Novartis AG Améliorations dans la préparation d'antigènes de vaccin contre le virus de la grippe
EP2233568A1 (fr) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Nouveau procédé pour la génération de virus d'ARN
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
EP2942062A1 (fr) 2009-02-10 2015-11-11 Novartis AG Posologies de vaccin antigrippal pour souches liées à une pandémie
US20120093860A1 (en) 2009-02-10 2012-04-19 Novartis Ag Influenza vaccines with increased amounts of h3 antigen
WO2010117786A1 (fr) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Vaccins pour le virus influenza et leurs utilisations
USH2284H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
JP5845180B2 (ja) 2009-07-30 2016-01-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルス及びそれらの使用
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
JP2013526849A (ja) 2010-03-30 2013-06-27 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
US20130183740A1 (en) 2010-06-02 2013-07-18 Avir Green Hills Biotechnology Research Development Trade Ag Novel method for generation of rna virus
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
SG11201400743VA (en) 2011-09-20 2014-04-28 Sinai School Medicine Influenza virus vaccines and uses thereof
CA2852857A1 (fr) 2011-10-20 2013-04-25 Novartis Ag Vaccins avec adjuvant contre le virus grippal b pour primo-vaccination pediatrique
EP2708552A1 (fr) 2012-09-12 2014-03-19 Medizinische Universität Wien Virus de la grippe
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
AU2013362935B2 (en) 2012-12-18 2018-10-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
BR112015017420A2 (pt) * 2013-01-23 2017-07-11 Novartis Ag recombinação de vírus influenza
US20140274806A1 (en) 2013-03-15 2014-09-18 Synthetic Genomics Vaccines Influenza virus reassortment
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
WO2014159960A1 (fr) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Anticorps contre l'hémagglutinine du virus de la grippe et utilisations correspondantes
KR102407019B1 (ko) 2014-02-27 2022-06-08 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 결합 방법
WO2015196150A2 (fr) 2014-06-20 2015-12-23 Wisconsin Alumni Research Foundation (Warf) Mutations conférant une stabilité génétique à des gènes supplémentaires dans des virus de la grippe
CL2014003146A1 (es) * 2014-11-20 2015-06-12 Univ Santiago Chile Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus.
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3261664A1 (fr) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Vaccin contre le virus de la grippe porcine bivalent
JP2018524323A (ja) 2015-06-26 2018-08-30 セキラス ユーケー リミテッド 抗原がマッチしたインフルエンザワクチン
US10416171B2 (en) 2015-07-07 2019-09-17 Seqirus UK Limited Influenza potency assays
JP2018530314A (ja) 2015-08-28 2018-10-18 ウィスコンシン アルムニ リサーチ ファンデイション ウイルス様粒子からの感染性インフルエンザウイルスの生成
JP7237344B2 (ja) 2016-06-15 2023-03-13 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルス血球凝集素タンパク質及びその使用
WO2018187706A2 (fr) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anticorps anti-neuraminidase du virus influenza de type b et leurs utilisations
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
WO2021041624A2 (fr) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Virus de la grippe recombinants à ha stabilisé pour réplication dans des oeufs
CN111363727B (zh) * 2020-01-20 2021-09-24 武汉大学 携带幽门螺杆菌的重组流感病毒、宿主细胞及其制备方法与应用
EP3896077A1 (fr) 2020-04-16 2021-10-20 Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH Particules de type virus de la grippe

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
EP1820853B1 (fr) * 1999-04-06 2011-09-21 Wisconsin Alumni Research Foundation Virus de la grippe recombinant pour vaccins et thérapie génétique

Also Published As

Publication number Publication date
DE122007000061I2 (de) 2011-07-21
DE122007000061I1 (de) 2007-12-20
ES2278621T5 (es) 2011-02-02
NL300294I1 (nl) 2007-12-03
DE60033284D1 (de) 2007-03-22
DE60033284T2 (de) 2007-10-25
FR08C0046I2 (fr) 2011-11-25
DE60033284T3 (de) 2014-10-30
EP1194580A1 (fr) 2002-04-10
NL300301I2 (nl) 2008-10-01
NL300369I1 (nl) 2009-01-05
CA2379012C (fr) 2013-07-02
DE122007000070I1 (de) 2008-01-31
CA2379012A1 (fr) 2001-01-18
NL300301I1 (nl) 2008-01-02
DK1194580T4 (da) 2011-01-03
WO2001004333A1 (fr) 2001-01-18
EP1194580B1 (fr) 2007-02-07
DE122008000057I1 (de) 2009-04-09
DK1194580T3 (da) 2007-04-10
CY2007023I1 (el) 2009-11-04
CY2007023I2 (el) 2009-11-04
DE122008000056I1 (de) 2009-04-09
NL300368I1 (nl) 2009-01-05
NL300368I2 (nl) 2017-08-03
NL300294I2 (nl) 2008-10-01
EP1194580B2 (fr) 2010-08-25
LU91367I2 (fr) 2007-11-21
CY1106404T1 (el) 2010-07-28
AU5998400A (en) 2001-01-30
ATE353370T1 (de) 2007-02-15
ES2278621T3 (es) 2007-08-16

Similar Documents

Publication Publication Date Title
FR08C0046I2 (fr) Reconstitution in vitro de virus a arn de polarite negative segmentes
CY1110964T1 (el) Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας
CA2401117A1 (fr) Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
CA2205015A1 (fr) Procede de production d'agents biologiques dans un milieu de culture sans proteines
DK1108787T3 (da) Fremstilling af vacciner
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
FR07C0012I2 (fr) Methode de desassemblage-reassemblage in vitro de particules viroides (vlp) du papillomavirus
DE69626022D1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
WO2003049767A3 (fr) Procede de production en serie de virus de l'hepatite a
BRPI0002694B8 (pt) processo de obtenção de vacina contra raiva em células vero, para uso humano
TH58373B (th) อิมมูโนเจนที่ถูกเพิ่มกำลัง สำหรับวัคซีนที่ไม่ถูกกระตุ้นเพื่อต่อสู้กับโรคที่เป็นการติดเชื้อที่มีสาเหตุมาจากกลุ่มของเจเปเนส เอนซีฟาลิทีสไวรัส และวิธีการเพื่อผลิตสิ่งนั้น